AIM WINNERS & LOSERS: SkinBioTherapeutics and Oxford Metrics make buys

Fri, 11th Oct 2024 10:38

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

----------

AIM - WINNERS

----------

SkinBioTherapeutics PLC, up 6.7% at 12.00 pence, 12-month range 7.00p-29.50p. The life science firm, with a focus on skin health, acquires Bio-Tech Solutions Ltd for GBP1.3 million. The deal is its second under its M&A strategy. The buy "brings the capabilities of manufacturing and packaging of health, hygiene and personal care products, and a future development platform for advanced topical creams", SkinBio adds. In addition, SkinBio reports it has a "sufficient cash runway" to support operations through to the summer of 2026.

----------

Oxford Metrics PLC, up 5.6% at 60.20 pence, 12-month range 55.00p-118.00p. The smart sensing and software provider for life sciences, entertainment and engineering markets announces a GBP6 million share buyback. It also reports it has acquired Sempre Group Holdings Ltd, a provider of measurement services which aims to solve "manufacturing challenges across multiple industries". It pays up to GBP5.5 million for Sempre.

----------

AIM - LOSERS

----------

Verici Dx PLC, down 16% at 5.49p, 12-month range 5.20p-13.00p. The developer of advanced clinical diagnostics for organ transplants says it now expects a US Medicare coverage determination process to continue into the first half of 2025. It had previously expected the process to conclude this year. "As such, the company will now recognise Tutivia revenues from this year in FY25. The updated timeline has no effect on the company's cash position at year end which we expect to be in line with market expectations," Verici says. Tutivia is a risk assessment tool which allows clinicians to identify those at a high risk of acute rejection, which is when a patient's body attacks a transplanted organ. Medicare coverage determination is a process where it is determined how much the US government will pay for a treatment.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com